Earnings ·
Reports $42.4M net loss for nine months ended September 30, 2026
EPRXEupraxia Pharmaceuticals Inc.
Eupraxia Pharmaceuticals Inc. reported a net loss of $42.4 million and cash used in operating activities of $34.6 million for the nine months ended September 30, 2026. The company raised approximately $58.6 million net from an equity offering on February 20, 2026, bringing total cash and short-term investments to $126.4 million at quarter-end. Research and development expenses increased significantly to $34.8 million as the company advances its EP-104 product candidates through clinical trials. Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company developing drug delivery technologies for unmet medical needs.